VAPEC-B regimen
WikiDoc Resources for VAPEC-B regimen |
Articles |
---|
Most recent articles on VAPEC-B regimen Most cited articles on VAPEC-B regimen |
Media |
Powerpoint slides on VAPEC-B regimen |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on VAPEC-B regimen at Clinical Trials.gov Trial results on VAPEC-B regimen Clinical Trials on VAPEC-B regimen at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on VAPEC-B regimen NICE Guidance on VAPEC-B regimen
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on VAPEC-B regimen Discussion groups on VAPEC-B regimen Patient Handouts on VAPEC-B regimen Directions to Hospitals Treating VAPEC-B regimen Risk calculators and risk factors for VAPEC-B regimen
|
Healthcare Provider Resources |
Causes & Risk Factors for VAPEC-B regimen |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Overview
VAPEC-B regimen refers to a regimen consisting of vincristine, doxorubicin (adriamycin), prednisolone, etoposide, cyclophosphamide, bleomycinused to treat non-Hodgkin's lymphoma (NHL).[1]
Regimen
VVincristine
ADoxorubicin (Adriamycin)
PPrednisolone
EEtoposide
CCyclophosphamide
BBleomycin
Indications
References
- ↑ 1.0 1.1 Singer JM, Mijovic A, Pettingale KW, Nethersell A, Dobbs HJ, Samaratunga IR; et al. (1995). "VAPEC-B chemotherapy in the treatment of aggressive non-Hodgkin's lymphoma: a retrospective analysis of 45 patients". Clin Oncol (R Coll Radiol). 7 (6): 366–70. PMID 8590697.